Keystone symposia – Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

Keystone symposia – Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

 

Biognosys is proud to present the highlights of a recent study in which we describe the potentialities of limited proteolysis for proteomics analysis. The oral presentation, “Limited proteolysis as a proteomics tool for target deconvolution and mechanistic insights – a test case,” will be held by our Scientific Director of Discovery Proteomics, Nigel Beaton, on May 25th.

 

Contact

    By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More